WO2018178060A1 - HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY - Google Patents
HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY Download PDFInfo
- Publication number
- WO2018178060A1 WO2018178060A1 PCT/EP2018/057744 EP2018057744W WO2018178060A1 WO 2018178060 A1 WO2018178060 A1 WO 2018178060A1 EP 2018057744 W EP2018057744 W EP 2018057744W WO 2018178060 A1 WO2018178060 A1 WO 2018178060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- drug
- mmol
- cancer
- conjugate according
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 177
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 177
- 102000003964 Histone deacetylase Human genes 0.000 title abstract description 22
- 108090000353 Histone deacetylase Proteins 0.000 title abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 76
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims abstract description 68
- 238000011282 treatment Methods 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 58
- 229960005395 cetuximab Drugs 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 55
- 229960000575 trastuzumab Drugs 0.000 claims description 53
- 210000004881 tumor cell Anatomy 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 21
- 230000021615 conjugation Effects 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 210000001072 colon Anatomy 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 14
- 230000002611 ovarian Effects 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 125000006850 spacer group Chemical group 0.000 claims description 13
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 235000018417 cysteine Nutrition 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000003573 thiols Chemical class 0.000 claims description 10
- 108010033040 Histones Proteins 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 238000002663 nebulization Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 229960001972 panitumumab Drugs 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 229960000397 bevacizumab Drugs 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 210000003128 head Anatomy 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000004303 peritoneum Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 229960000106 biosimilars Drugs 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 241000208140 Acer Species 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 abstract description 23
- 108060006698 EGF receptor Proteins 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract description 9
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 6
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 6
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract description 6
- 102000056372 ErbB-3 Receptor Human genes 0.000 abstract description 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- 239000000243 solution Substances 0.000 description 88
- 210000004027 cell Anatomy 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- 239000007787 solid Substances 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- 239000002904 solvent Substances 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- QGYPCQAYENIOOF-UHFFFAOYSA-N s-[7-anilino-7-oxo-6-[(5-oxopyrrolidine-2-carbonyl)amino]heptyl] ethanethioate Chemical compound C=1C=CC=CC=1NC(=O)C(CCCCCSC(=O)C)NC(=O)C1CCC(=O)N1 QGYPCQAYENIOOF-UHFFFAOYSA-N 0.000 description 36
- -1 NHS esters Chemical class 0.000 description 32
- 238000001704 evaporation Methods 0.000 description 32
- 230000008020 evaporation Effects 0.000 description 32
- 238000003818 flash chromatography Methods 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 230000000259 anti-tumor effect Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 238000007912 intraperitoneal administration Methods 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 238000012512 characterization method Methods 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000002952 image-based readout Methods 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 230000005917 in vivo anti-tumor Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 210000000496 pancreas Anatomy 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000021736 acetylation Effects 0.000 description 9
- 238000006640 acetylation reaction Methods 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 238000007911 parenteral administration Methods 0.000 description 8
- 238000011466 pressurized intraperitoneal aerosol chemotherapy Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 7
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 7
- 102000006947 Histones Human genes 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 7
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- HCMIHWOGHFABTM-UHFFFAOYSA-N 4-[[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound O=C1N(C(C=C1)=O)CCCCCC(=O)NCC1CCC(CC1)C(=O)O HCMIHWOGHFABTM-UHFFFAOYSA-N 0.000 description 6
- IRKIVQOPWMXRLA-UHFFFAOYSA-N 4-[[6-[3-[7-anilino-7-oxo-6-[(5-oxopyrrolidine-2-carbonyl)amino]heptyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound O=C1N(C(CC1SCCCCCC(C(NC1=CC=CC=C1)=O)NC(=O)C1NC(CC1)=O)=O)CCCCCC(=O)NCC1CCC(CC1)C(=O)O IRKIVQOPWMXRLA-UHFFFAOYSA-N 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- KHBREXBINRCDMZ-URXFXBBRSA-N ethyl 7-[[(2S)-1-[[(2S)-1-[4-(bromomethyl)anilino]-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-7-oxoheptanoate Chemical compound BrCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)NC(CCCCCC(=O)OCC)=O)=O)=O KHBREXBINRCDMZ-URXFXBBRSA-N 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 231100000782 microtubule inhibitor Toxicity 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N phenyl mercaptan Natural products SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- XBKHQENGCLDART-UHFFFAOYSA-N (4-sulfanylphenyl)methanol Chemical compound OCC1=CC=C(S)C=C1 XBKHQENGCLDART-UHFFFAOYSA-N 0.000 description 5
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 5
- JMLACNBSUPVBSI-UHFFFAOYSA-N 6-[3-[4-(bromomethyl)phenyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]-N-prop-2-ynylhexanamide Chemical compound BrCC1=CC=C(C=C1)SC1C(N(C(C1)=O)CCCCCC(=O)NCC#C)=O JMLACNBSUPVBSI-UHFFFAOYSA-N 0.000 description 5
- OHQFLBMAHZJOJA-AATRIKPKSA-N 6-[[(e)-3-carboxyprop-2-enoyl]amino]hexanoic acid Chemical compound OC(=O)CCCCCNC(=O)\C=C\C(O)=O OHQFLBMAHZJOJA-AATRIKPKSA-N 0.000 description 5
- JCORXJUUSVCJEP-UHFFFAOYSA-N 6-azidohexanoic acid Chemical compound OC(=O)CCCCCN=[N+]=[N-] JCORXJUUSVCJEP-UHFFFAOYSA-N 0.000 description 5
- HRTOFBWCNHKPDC-NSOVKSMOSA-N 9H-fluoren-9-yl N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)OC(N([C@H](C(=O)N[C@H](C(=O)NC1=CC=C(C=C1)CO)CCCNC(=O)N)C(C)C)C)=O HRTOFBWCNHKPDC-NSOVKSMOSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 5
- 229950009221 chidamide Drugs 0.000 description 5
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 229950005259 dacinostat Drugs 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- JPJMNCROLRPFHI-QFIPXVFZSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)ON1C(=O)CCC1=O JPJMNCROLRPFHI-QFIPXVFZSA-N 0.000 description 4
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 4
- VEGGTWZUZGZKHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)NC1=CC=C(CO)C=C1 VEGGTWZUZGZKHY-GJZGRUSLSA-N 0.000 description 4
- ZJLNQOIFTYLCHC-VXKWHMMOSA-N (2s)-5-(carbamoylamino)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(O)=O)C3=CC=CC=C3C2=C1 ZJLNQOIFTYLCHC-VXKWHMMOSA-N 0.000 description 4
- RGBFGCSTAMHTKM-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)ethylcarbamic acid Chemical compound OC(=O)NCCN1C(=O)C=CC1=O RGBFGCSTAMHTKM-UHFFFAOYSA-N 0.000 description 4
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 description 4
- FZWBHZFWXDTUFA-HOZVWGBUSA-N 4-[[3-[(6S)-7-anilino-7-oxo-6-[(5-oxopyrrolidine-2-carbonyl)amino]heptyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]methyl]cyclohexane-1-carboxylic acid Chemical compound O=C1N(C(CC1SCCCCC[C@@H](C(NC1=CC=CC=C1)=O)NC(=O)C1NC(CC1)=O)=O)CC1CCC(CC1)C(=O)O FZWBHZFWXDTUFA-HOZVWGBUSA-N 0.000 description 4
- BHVQGWVDBLEVRG-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)-n-prop-2-ynylhexanamide Chemical compound C#CCNC(=O)CCCCCN1C(=O)C=CC1=O BHVQGWVDBLEVRG-UHFFFAOYSA-N 0.000 description 4
- ZRYQAHLLNOFXNP-UHFFFAOYSA-N 6-[3-[4-(hydroxymethyl)phenyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]-N-prop-2-ynylhexanamide Chemical compound OCC1=CC=C(C=C1)SC1C(N(C(C1)=O)CCCCCC(=O)NCC#C)=O ZRYQAHLLNOFXNP-UHFFFAOYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 4
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- BDZULQWFYDXGGY-UHFFFAOYSA-N N'-[[4-[2,5-dioxo-1-[6-oxo-6-(prop-2-ynylamino)hexyl]pyrrolidin-3-yl]sulfanylphenyl]methoxy]-N-phenyloctanediamide Chemical compound O=C1N(C(CC1SC1=CC=C(CONC(CCCCCCC(=O)NC2=CC=CC=C2)=O)C=C1)=O)CCCCCC(NCC#C)=O BDZULQWFYDXGGY-UHFFFAOYSA-N 0.000 description 4
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 4
- 238000011789 NOD SCID mouse Methods 0.000 description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 4
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- VDBFUEJMGIGXEU-DLQLMDMZSA-N 2-[2-[2-[2-[2-[2-[2-[[4-[[3-[(6S)-7-anilino-7-oxo-6-[(5-oxopyrrolidine-2-carbonyl)amino]heptyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]methyl]cyclohexanecarbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid Chemical compound O=C1N(C(CC1SCCCCC[C@@H](C(NC1=CC=CC=C1)=O)NC(=O)C1NC(CC1)=O)=O)CC1CCC(CC1)C(NCCOCCOCCOCCOCCOCCOCC(=O)O)=O VDBFUEJMGIGXEU-DLQLMDMZSA-N 0.000 description 3
- AZQIITUVXBDNFW-UHFFFAOYSA-N 2-carbamoylbut-3-enoic acid Chemical compound NC(=O)C(C=C)C(O)=O AZQIITUVXBDNFW-UHFFFAOYSA-N 0.000 description 3
- FKAWETHEYBZGSR-UHFFFAOYSA-N 3-methylidenepyrrolidine-2,5-dione Chemical compound C=C1CC(=O)NC1=O FKAWETHEYBZGSR-UHFFFAOYSA-N 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical group OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 0 CCC(CC(N1CCN*C)O)C1=O Chemical compound CCC(CC(N1CCN*C)O)C1=O 0.000 description 3
- PVWOQAUGICFSIP-UHFFFAOYSA-N ClC1=C(C(=C(C(=O)OC(C2=C(C(=C(C=C2)Cl)Cl)Cl)=O)C=C1)Cl)Cl Chemical compound ClC1=C(C(=C(C(=O)OC(C2=C(C(=C(C=C2)Cl)Cl)Cl)=O)C=C1)Cl)Cl PVWOQAUGICFSIP-UHFFFAOYSA-N 0.000 description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 3
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002001 anti-metastasis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 201000002628 peritoneum cancer Diseases 0.000 description 3
- 150000003017 phosphorus Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 2
- NQYXFXWKKYGBNL-UHFFFAOYSA-N 7-ethoxy-7-oxoheptanoic acid Chemical compound CCOC(=O)CCCCCC(O)=O NQYXFXWKKYGBNL-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- OHZGQBFQNFBVPS-UHFFFAOYSA-N CC(C(N(CCNC)C1=O)=O)=C1Br Chemical compound CC(C(N(CCNC)C1=O)=O)=C1Br OHZGQBFQNFBVPS-UHFFFAOYSA-N 0.000 description 2
- HNEJGQFWWSRXEZ-UHFFFAOYSA-N CC(CC(N1CCOCCC(NCCNC)=O)=O)C1=O Chemical compound CC(CC(N1CCOCCC(NCCNC)=O)=O)C1=O HNEJGQFWWSRXEZ-UHFFFAOYSA-N 0.000 description 2
- NWGGYRHMRZCLQA-UHFFFAOYSA-N CCC(CC(O)=O)C(NCCNC)=O Chemical compound CCC(CC(O)=O)C(NCCNC)=O NWGGYRHMRZCLQA-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 241000766026 Coregonus nasus Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010061137 Ocular toxicity Diseases 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 229950005837 entinostat Drugs 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000011462 intraperitoneal chemotherapy Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960005558 mertansine Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 231100000327 ocular toxicity Toxicity 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000011499 palliative surgery Methods 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- RTSHJILODKDMMC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[[6-[3-[7-anilino-7-oxo-6-[(5-oxopyrrolidine-2-carbonyl)amino]heptyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoylamino]methyl]cyclohexane-1-carboxylate Chemical compound O=C1N(C(CC1SCCCCCC(C(NC1=CC=CC=C1)=O)NC(=O)C1NC(CC1)=O)=O)CCCCCC(=O)NCC1CCC(CC1)C(=O)ON1C(CCC1=O)=O RTSHJILODKDMMC-UHFFFAOYSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- BUASFOVDIKRABD-UHFFFAOYSA-N 1,5-dimethoxy-2h-triazine Chemical compound CON1NN=CC(OC)=C1 BUASFOVDIKRABD-UHFFFAOYSA-N 0.000 description 1
- ODVRLSOMTXGTMX-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione Chemical compound NCCN1C(=O)C=CC1=O ODVRLSOMTXGTMX-UHFFFAOYSA-N 0.000 description 1
- YNHKVOGCDPODMT-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCCN1C(=O)C=CC1=O YNHKVOGCDPODMT-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 1
- PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 1
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
- DPRULTZUGLDCPZ-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCN=[N+]=[N-] DPRULTZUGLDCPZ-UHFFFAOYSA-N 0.000 description 1
- MKAZMNJXEMDNQF-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl N-[2-(2,5-dioxopyrrol-1-yl)ethyl]carbamate Chemical compound O=C1N(C(C=C1)=O)CCNC(OCCOCCOCCOCCOCCOCCNC)=O MKAZMNJXEMDNQF-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- NVRVNSHHLPQGCU-UHFFFAOYSA-N 6-bromohexanoic acid Chemical compound OC(=O)CCCCCBr NVRVNSHHLPQGCU-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001351283 Arta Species 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- DRDLBHXLCVQPAA-UHFFFAOYSA-N CC(C)NCC(CC1)CCC1C(C)=O Chemical compound CC(C)NCC(CC1)CCC1C(C)=O DRDLBHXLCVQPAA-UHFFFAOYSA-N 0.000 description 1
- BKNMAUFIUMGVCC-UHFFFAOYSA-N CC(C)NCCN(C(C(C)C1)O)C1=O Chemical compound CC(C)NCCN(C(C(C)C1)O)C1=O BKNMAUFIUMGVCC-UHFFFAOYSA-N 0.000 description 1
- VPXDUEITFUQZRL-UHFFFAOYSA-N CC(CC(N1CCNC)O)C1=O Chemical compound CC(CC(N1CCNC)O)C1=O VPXDUEITFUQZRL-UHFFFAOYSA-N 0.000 description 1
- MWXZYEKQKCKVAN-GUEIFIIISA-N CC(CC1)N[C@H]1C(N[C@@H](CCCCCSC(CC(N1CCCCCC(NCC(CC2)CCC2C(NCCN(C(C=C2)=O)C2=O)=O)=O)=O)C1=O)C(Nc1ccccc1)=O)=O Chemical compound CC(CC1)N[C@H]1C(N[C@@H](CCCCCSC(CC(N1CCCCCC(NCC(CC2)CCC2C(NCCN(C(C=C2)=O)C2=O)=O)=O)=O)C1=O)C(Nc1ccccc1)=O)=O MWXZYEKQKCKVAN-GUEIFIIISA-N 0.000 description 1
- XGTYCTIFMHVROF-UHFFFAOYSA-N CC(CCCCC[n]1nnc(CNC)c1)=O Chemical compound CC(CCCCC[n]1nnc(CNC)c1)=O XGTYCTIFMHVROF-UHFFFAOYSA-N 0.000 description 1
- KPQVNEQBFKIHOW-GCPJXAAMSA-N CC([C@H](CCCCCSC(CC(N1C[C@H](CC2)CC[C@@H]2C(C(NCCOCCO)=O)=C)=O)C1(C)O)NC([C@@H](CC1)NC1=O)=O)(Nc1ccccc1)O Chemical compound CC([C@H](CCCCCSC(CC(N1C[C@H](CC2)CC[C@@H]2C(C(NCCOCCO)=O)=C)=O)C1(C)O)NC([C@@H](CC1)NC1=O)=O)(Nc1ccccc1)O KPQVNEQBFKIHOW-GCPJXAAMSA-N 0.000 description 1
- VPDZETHWDDHFHB-UHFFFAOYSA-N CCCOCC(NCCN(C(C=C1)=O)C1=O)=O Chemical compound CCCOCC(NCCN(C(C=C1)=O)C1=O)=O VPDZETHWDDHFHB-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010051676 Metastases to peritoneum Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- SHYMHDDMXRVUFN-UHFFFAOYSA-N NCCN(C(CC1)=O)C1=O Chemical compound NCCN(C(CC1)=O)C1=O SHYMHDDMXRVUFN-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- PZTGCDZKIBOGKC-ZYMOGRSISA-N O=C(CC(CCCCCCS)NC([C@@H](CC1)NC1=O)=O)Nc1ccccc1 Chemical compound O=C(CC(CCCCCCS)NC([C@@H](CC1)NC1=O)=O)Nc1ccccc1 PZTGCDZKIBOGKC-ZYMOGRSISA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 244000052585 Rosa centifolia Species 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229940077840 beleodaq Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ZSCYJHGJGRSPAB-UHFFFAOYSA-N carbamic acid Chemical compound NC(O)=O.NC(O)=O ZSCYJHGJGRSPAB-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- SFKFUZBTNJFADV-BAOFOTJISA-N ethyl 7-[[(2S)-1-[[(2S)-1-[4-[[(8-anilino-8-oxooctanoyl)amino]oxymethyl]anilino]-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-7-oxoheptanoate Chemical compound CC([C@@H](C(N[C@H](C(NC1=CC=C(C=C1)CONC(CCCCCCC(NC1=CC=CC=C1)=O)=O)=O)CCCNC(=O)N)=O)NC(CCCCCC(=O)OCC)=O)C SFKFUZBTNJFADV-BAOFOTJISA-N 0.000 description 1
- BPINPGAJBUZROT-URXFXBBRSA-N ethyl 7-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-7-oxoheptanoate Chemical compound OCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)NC(CCCCCC(=O)OCC)=O)=O)=O BPINPGAJBUZROT-URXFXBBRSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- CFKBMXXDXYFDET-UHFFFAOYSA-N n-phenyl-7-sulfanylheptanamide Chemical compound SCCCCCCC(=O)NC1=CC=CC=C1 CFKBMXXDXYFDET-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000010918 peritoneal neoplasm Diseases 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Definitions
- ADCs HDAC Inhibitors-based antibody drug conjugates
- the present invention is directed to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates useful for the treatment of proliferative diseases.
- HDACi Histone Deacetylase Inhibitors
- the invention particularly relates to an antibody-drug-conjugate comprising an antibody directed to ErbB1 , ErbB2, ErbB3 receptors or related molecular targets.
- the invention further provides new HDAC inhibitor drugs comprised by the antibody- drug-conjugates.
- the invention relates to ADCs pharmaceutical compositions and their use in the treatment of cancer or tumors and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
- Epigenetic aberrations can contribute to the onset and progression of the above mentioned human diseases via the gain or loss of function of epigenetic regulatory proteins (Berdasco, 2013 Hum Genet 132: 359-83), because over 1 ,750 proteins in human cells can be post-translationally modified at lysine residues via acetyla- tion and deacetylation (Choudhary 2009 Science 325: 834-40).
- Deacetylating enzymes are considered as valuable targets to treat aberrant deacetylation related to cancer but also various other diseases such neurological disorders, inflammation, viral infections and cardiovascular disorders (Minucci 2006 Nature Rev Cancer 6: 38-51; Glozak 2007 Oncogene 26: 5420-32; Zhang 2015 Med Res Rev 35: 63-84; Dinarello 2010 Mol Med 17: 333-52).
- panobino- stat (Farydak®, Novartis) has been approved by the FDA, as combination therapy with bortezomib and dexamethasone in patients with recurrent multiple myeloma (Garnock-Jones KP (2015) Drugs. 75: 695-704).
- HDAC inhibitors are mostly studied as anticancer agents, but there is a growing body of literature ascribing HDAC enzymes to play a crucial role in other diseases such as neurological disorders, inflammatory processes and viral infections [Dinarello 2010 Cell 140: 935-950; Gray 2011 Epigenomics 3: 431-450; Giannini 2012 Future Med Chem 4: 1439-60).
- WO2015/157595 describes conjugates of cysteine engineered antibodies and heterologous moiety.
- heterologous moiety there are mentioned drugs, and among drugs, there are Histone deacetylase inhibitors (HDAC).
- HDAC Histone deacetylase inhibitors
- Choi S et al in J Control. Release 152, suppl.1, 2011, e9-e10a describes a generic HDACi conjugate with CD7 antibody, through PLGA nanoparticles. The conjugate would be able to deliver the HDAC inhibitors to human T cell, whit ovary CD7 receptor. This document does not report any specific conjugate.
- HDACi HDAC inhibitor derivatives with folic acid, retinoic acid, platinum based agents, protein kinase inhibitors and Inosine monophosphate dehydrogenase inhibitors.
- HDACs 1 , 2 and 3 primarily nuclear have been found expecially in late stage, aggressive malingnacies in tumor cells and they have correlated with poor survival rates (Gryder 2012 Future Med Chem 4: 505-24); HDAC6 primary cellular localization in the cytoplasm, regulates acetylation states and thereby the functionality of tubulin, HSP90 and other extranuclear proteins, thus suggesting its involvement in removal of misfolded proteins in cells, cell motility and metastatic potential ⁇ Clawson 2016 Ann Transl Med 4: 287).
- HDAC isoforms (2, 3, 6, 9, 10) are also involved in chronic intestinal inflammation, so HDAC inhibitors in addition to apoptosis induction of tumor cells can be used for inflammatory bowel disease (Felice 2015 Aliment Pharmacol Ther 41: 26-38).
- ST7612AA1 exhibits the peculiarity to inhibit the growth of several tumors such as Ras-mutant colon carcinoma, a subset of strongly proliferating dedifferentiated colon cancer, associated with reduced patient survival; non small cell lung tumors with wild type EGFR (and mutant KRAS) and T790 EGFR mutation; ovarian with low levels of PTEN and overexpression of ErbB1 and ErbB2 or ovarian cancer without PTEN; triple-negative breast cancer (TNBC) defined by the absence of estrogen receptor, progesterone receptor and ErbB2; acute myeloid leukemia, diffuse large B cell lymphoma.
- tumors such as Ras-mutant colon carcinoma, a subset of strongly proliferating dedifferentiated colon cancer, associated with reduced patient survival; non small cell lung tumors with wild type EGFR (and mutant KRAS) and T790 EGFR mutation; ovarian with low levels of PTEN and overexpression of ErbB1 and ErbB2 or ovarian cancer without PTEN; triple-negative breast cancer
- ST7612AA1 showed to modulate some transcripts involved in immune response and in key pathogenetic pathways, such NF-KB pathway and epithelial-mesenchymal transition (EMT), thus suggesting a relevant implication not only in cancer but also in the inflammatory diseases (Vesci 2015 OncoTarget 20: 5735-48).
- ST7612AA1 The action of ST7612AA1 is exerted against both nuclear and cytoplasmatic HDAC isoforms of tumor cells, leading to increased transcription of e-cadherin, keratins and other typical epithelial markers and, concomitantly, down-regulation of vimentin and other genes associated to the mesenchymal phenotype.
- EMT epithelial-mesenchymal-transition
- ST7612AA1 was also able to target nonhistone HDAC substrates like, for example, TP53, a/pfta-tubulin or the heat shock protein 90 (HSP90) involved in DNA damage signaling, transcription factor binding, molecular homeostasis and DNA repair processes.
- ST7612AA1 proved to be able to induce HIV reactivation being potentially useful for new therapies aiming at the eradication of the viral reservoirs (Badia 2015 Antiviral Res 123: 62-9).
- ADC Antibody-drug conjugates
- microtubule inhibitors are clinically validated ADC payloads.
- Kadcyla Trastuzumab emtansine; Genentech
- Adcetris brentuximab vedotin; Seattle Genetics
- Besponsa Inotuzumab ozogamicin; Pfizer
- Mylotarg Gemtuzumab Ozogamicin; Pfizer
- the payloads currently utilized in ADCs are highly potent cytotoxic drugs, exerting their effects on critical cellular processes required for survival.
- Highly potent microtubule inhibitors such as maytansine derivatives (DM1/DM4) or auristatins (MMAE/MMAF) dominate the current ADC landscape. These typically induce apoptosis in cells undergoing mitosis by causing cell cycle arrest at G2/M. More recent works show that microtubule inhibitors may also disrupt non-dividing cells in interphase.
- cytotoxic drugs used in ADCs include ene- diynes (calicheamicin), duocarmycin derivatives, pyrrolobenzodiazepines (PBDs) and indolinobenzodiazepines, all of which target the minor groove of DNA, and quinoline alkaloids (SN-38), which inhibit topoisomerase I.
- ADC toxicity is thought to be derived from the payload release due to linker instability. Rapidly dividing normal cells such as cells lining the digestive tract, cells in the hair follicles and myeloid cells are at risk of toxicity from released microtubule inhibitors resulting in gastrointestinal symptoms, hair loss and myelo- suppression. Some key toxicities are found with different payloads.
- MMAE induces peripheral neuropathy and neutropenia
- MMAF is associated with thrombocytopenia and ocular toxicities
- DM1 causes gastrointestinal effects as well as thrombocytopenia and neutropenia, depending on the linker and consequent metabolites
- ocular toxicity is the most common adverse event with DM4- conjugated ADCs
- calicheamicin causes thrombocytopenia and hepatic dysfunction
- early indications from SN-38 conjugated drugs suggests neutropenia as a frequent toxicity.
- a possible strategy to minimize toxicity of next generation ADCs is the selection of low toxicity payloads.
- the present invention surprisingly demonstrates that antibody-drug-conjugates made of an anti-tumor antibody, conjugated to a drug with low toxicity such as an HDACi, can exert excellent efficacy in vivo.
- epigenetic modulators i.e. HDACi
- HDACi epigenetic modulators
- other epigenetic modulators that modulate gene expression without altering the DNA base sequence such as DNA methyltransferase inhibitors (azacitidine and decitabine) could be used (Pachaiyappan 2014 Bioorg and Med Chem Lett 24: 21-32).
- the antibody-drug-conjugate is further to have a good stability in blood and body fluids and excellent anti-cancer activity while having low toxicity compared to antibody-drug-conjugates of the prior art. It is therefore an object of the present invention to provide an antibody-drug- conjugate comprising a safe anti-cancer drug conjugated to an antibody. Another object of the present invention is to provide a method for preparing said antibody- drug-conjugate (ADC).
- ADC antibody- drug-conjugate
- a further object of the present invention is to provide a pharmaceutical composition comprising said antibody-drug-conjugate.
- Yet another object of the present invention is to provide said antibody-drug- conjugate for use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
- the present invention relates to antibody-drug-conjugates of Formula (I)
- D is a cytotoxic drug (also referred to as warhead), is a histone deacetylase inhibitor drug that contains benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG),
- CU is a connecting unit, which may be absent or which is selected from
- S1 is a spacer and may be absent or is
- L is a linker, which is selected from (CH 2 )q-CO, NH-(CH 2 )r-(PEG)s-(CH 2 )w-CO, NH-CO-(CH 2 )r-(PEG)s-X-(CH 2 )w-CO, wherein X may be absent, NH or O, q is an integer of 2-8, r may be absent or is an integer of 1 -4, s may be absent or is an integer of 1 -6, and w may be absent or an integer of 1 -2,
- S2 is a spacer and may be absent or is
- CG is a connecting group fornned after conjugation to the cysteine thiol- or lysine amino- groups of the antibodies, which can be absent or one of following moieties:
- y is an integer of 0 to 8.
- Ab is an antibody or an antigen binding fragment thereof, and m, n, o and p represent integers of 0 or 1 .
- the linker (L) is preferably selected from
- n is an integer of 2-5.
- a payload is a toxin (HDAC inhibitor) linked to a suitable linker / spacer, which ends with groups (i.e., maleimide, NHS esters) suitable for conjugation to antibodies and comprises the following part of formula I:
- (CG)' in the payloads of Formula II may be NHS (N- hydroxysuccinimide) or an activated acylderivative (including pentaflurophenyl ester, p-nitro and 2,4-dinitrophenol ester, thiophenol ester, acylimidazole, isobutyl- carbonate, trichlorobenzoic anhydride), or maleimide- or 3-methylenesuccinimide, 3,4-dibromo maleimide or ⁇ amino-carbonyl ⁇ -3-butenoic acid of the following formulae:
- the present invention relates to ADCs having as warhead an HDAC inhibitor, is selected from thiol-based histone deacetylase inhibitors, such as ST7464AA1 and ST7660AA1 (a thiol analogue of vorinostat), having the following formulas:
- Thiol-based SAHA (Vorinostat) analogue Thiol (active drug) of corresponding thioacetyl ST7612AA1 (prodrug) or from hydroxamic acid based histone deacetylase inhibitors (HDACs), such as vorinostat (SAHA), panobinostat (LBH589), or dacinostat (LAQ824) having the following formulas:
- HDACs histone deacetylase inhibitors
- MS275 entino- stat
- the histone deacetylase inhibitor and the payload comprising D-(CU), (S2)-(CG)' P - may be a compound selected from:
- the invention relates to antibody-drug-conjugates, wherein the histone deacetylase inhibitor drug and the payload comprising the structure D-(CU) m -(S1 )n-L-(S2)-(CG)' P are selected from:
- the invention relates to payload-drug-conjugates, wherein payload-drug conjugate is selected from:
- the antibody-drug-conjugates derived from the compounds of 1 -23.
- the ADC are selected from the compounds represented by the formulas 24- 37:
- the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a derivative of Formula I with pharmaceutically acceptable excipients.
- composition may be for enteral or parenteral administration, wherein the enteral administration comprises oral, aerosol, rectal or buccal route, and parenteral administration comprises subcutaneous, intramuscular or intravenous, and intradermic route.
- the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a derivative of Formula I in combination with other known anticancer treatments such as radiation therapy or chemotherapy regiment, in combination with cytostatic or cytotoxic agents, antibiotic -type agents, alkylating agents, antimetabolite agents , hormonal agents, interferon type agents, cyclooxygenase inhibitors (e.g.
- COX-2 inhibitors COX-2 inhibitors
- metalloproteinase inhibitors telomerase inhibitors
- tyrosine kinase inhibitors anti-grow factor receptor agents
- anti-HER2 agents anti-EGFR agents
- anti-angiogenesis agents e.g. angiogenesis inhibitors
- farnesyl transferase inhibitors ras-raf signal transduction pathway inhibitors
- cell cycle inhibitors other cdks inhibitors
- tubulin binding agents topoiso- merase I inhibitors, topoisomerase II inhibitors, and the like.
- the invention provides a product comprising a derivative of Formula (I) or a pharmaceutically acceptable salt thereof, as defined above, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- the invention provides a derivative of Formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.
- the present invention moreover relates to the antibody-drug-conjugates or a pharmaceutical composition comprising the drug antibody conjugates of the invention for use in the treatment of cancer or tumour.
- the invention particularly relates to the treatment of a cancer or tumour expressing ErbB1 , ErbB2 and/or ErbB3 receptors.
- carcinomas including bladder, breast, colon, kidney, liver, lung, comprising small cell lung cancer, oesophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin carcinoma, comprising squamous cell carcinoma; hematopoietic tumours of lymphoid lineage, including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumours of myeloid lineage, including acute and chronic myelogenous leukaemia, myelodysplastic syndrome and promyelocy- tic leukaemia; tumours of mesenchymal origin, including fibrosarcoma
- the HIV reactivation induced by the HDACi-based ADCs can be potentially useful for new therapies aiming at the eradication of the viral reservoirs (Badia 2015 Antiviral Res 123: 62-9).
- the above described antibody- drug-conjugates may be used as an adjuvant therapeutic in the treatment of HIV.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising said antibody-drug-conjugates as well as to said antibody-drug-conjugates or said pharmaceutical composition for use in the treatment of a cancer or a tumor expressing a receptor selected from ErbB1 , ErbB2 or ErbB3.
- the antibody-drug-conjugates of the present invention were more potent than the single antibodies and the cytotoxic agent, given at the same concentration, route and schedule. Moreover, it was surprising that the cytotoxic agent such as an HDAC inhibitor conjugated to the antibodies, at suboptimal dosages, resulted very effective, not depending on the linkers or type conjugation (lysine or cysteine). Subsequently, these HDAC inhibitors-based ADCs allow obtaining antitumor efficacy at lower dosages than the corresponding antibodies, thus resulting in minor toxicity.
- Figure 1 shows MALDI mass spectra of Cetuximab (up) and of its conjugated forms ST8154AA1 (24) with payload-NHS ST8128AA1 (1) (down). The DAR calculated from the mass difference was 8.9.
- Figure 2 shows MALDI mass spectra of Trastuzumab (up) and of its conjugated forms ST8178AA1 (27) with payload-NHS ST8128AA1 (1) (down). The DAR calculated from the mass difference was 6.9.
- Figure 3 shows binding (FACS analysis) of native Cetuximab and Cetuximab- derived ADCs, ST8154AA1 (24) and ST8177AA1 (26) (A) or ST8219AA1 (37) (B), to different tumor cell lines.
- Grey peaks refer to cells without primary antibody.
- Figure 4 shows binding (FACS analysis) of native Trastuzumab and Trastuzumab- derived ADCs, ST8178AA1 (27) and ST8176AA1 (28) (A), or ST8205AA1 (30) and ST8218AA1 (36) (B), to different tumor cell lines.
- Grey peaks refer to cells without primary antibody.
- Figure 5 shows immunoreactivity of ADCs, tested by antigen-specific ELISA. Activity measured against A) recombinant human EGF-R/Erb1 Fc chimera, or B) recombinant Human ErbB2/HER2 protein. Detection through anti-human K light chain horseradish peroxidase (HRP)-conjugated antibody and TMB substrate addition. Optical density at 450 nm measured by ELISA spectrophotometer. Results are the mean ( ⁇ SD) of two independent replicates.
- HRP horseradish peroxidase
- Figure 6 shows antiproliferative activity of ST8154AA1 (24) on NCI-H1975 non- small cell lung carcinoma cells upon 6 days of treatment.
- IC50 value ⁇ SD of the ADC was 250 ⁇ 10 nM, in comparison with Cetuximab, which was ineffective (IC50 >500 nM).
- Figure 7 shows antiproliferative activity of ST8154AA1 (24) on Calu-3 non-small cell lung carcinoma cells upon 6 days of treatment.
- IC50 value ⁇ SD of the ADC was 450 ⁇ 10 nM, in comparison with Cetuximab, which was ineffective (IC50 >500 nM).
- Figure 8 shows the effect of Cetuximab-derived ADCs ST8154AA1 (24) and ST8177AA1 (26) (A), or ST8219AA1 (37) (B), on the level of acetylated-a-tubulin in different tumor cell lines. Cells were cultivated 3 hours at 37°C with antibodies (5 pg/nriL).
- HCS High Content Screening
- Figure 9a and Figure 9b show the effect of Trastuzumab-derived ADCs ST8178AA1 (27) and ST8176AA1 (28) (A), or ST8202AA1 (31), ST8205AA1 (30) and ST8218AA1 (36) (B), on the level of acetylated-a-tubulin in different tumor cell lines.
- Cells were cultivated 3 hours at 37°C with antibodies (5 pg/mL). Following two washings, cells were then fixed and stained with mouse anti-acetylated-a- tubulin IgG and then with FITC-conjugated goat anti-mouse IgG. Draq5 dye staining of nucleus and cytoplasm.
- Insets show fluorescence signals specifically associated to acetylated-a-tubulin. Fluorescence imaging by High Content Screening (HCS) Operetta. Each image is representative of at least 5 fields of duplicate wells. Magnification 60x. Data are from one representative experiment out of two.
- Figure 10 shows the effect of Cetuximab-derived ADCs ST8154AA1 (24) and ST8177AA1 (26) (A), or ST8219AA1 (37) (B), on the level of acetylated-histone H3 in different tumor cell lines.
- Cells were cultivated 3 hours at 37°C with antibodies (5 g/mL). Following two washings, cells were then fixed and stained with rabbit anti-acetylated-histone H3 IgG and then with FITC-conjugated goat anti-rabbit IgG. Draq5 dye staining of nucleus and cytoplasm. Insets show fluorescence signals specifically associated to acetylated-histone H3. Fluorescence imaging by High Content Screening (HCS) Operetta.
- HCS High Content Screening
- FIG. 11 shows the effect of Trastuzumab-derived ADCs ST8178AA1 (27) and ST8176AA1 (28) (A), or ST8202AA1 (31), ST8205AA1 (30) and ST8218AA1 (36) (B), on the level of acetylated-histone H3 in different tumor cell lines.
- Cells were cultivated 3 hours at 37°C with antibodies (5 pg/nriL). Following two washings, cells were then fixed and stained with rabbit anti-acetylated-histone H3 IgG and then with FITC-conjugated goat anti-rabbit IgG.
- Draq5 dye staining of nucleus and cytoplasm Insets show fluorescence signals specifically associated to acetylated-a- histone H3. Fluorescence imaging by High Content Screening (HCS) Operetta. Each image is representative of at least 5 fields of duplicate wells. Magnification 60x. Data are from one representative experiment out of two.
- Figure 12 shows the effect of ADCs on acetylation of a-tubulin and histone H4 in A549 (A) and SKBR3 (B) cell lines.
- Cells were cultivated 3 hours at 37°C with antibodies (20 Mg/mL) and then Western Blot analysis was carried out on total protein lysates. Representative blots are shown.
- Figure 13 shows the antitumor activity of ST8155AA1 (25), ST8154AA1 (24), and ST7612AA1 given intraperitoneally according to the schedule q4dx4, in comparison with Cetuximab in sc NCI-H1975 tumor bearing mice.
- Tumor cells (5x10 6 ). were sc injected in the right flank of mice The ADCs and Cetuximab were given at a dose of 50 mg/kg, whereas ST7612AA1 at 120 mg/kg.
- Figure 15 shows the antimetastatic activity of ST8154AA1 (24) in comparison with Cetuximab (Ctx) on artificial metastatic lung cancer resulting from the injection of 5x10 6 A549-luc-C8 (A549luc) cells into the tail vein of immunodeficient SCID/beige mice.
- Tumor bioluminescence imaging (BLI) was recorded by Xenogen S Imaging System 200, at different time points (+35, +49 and +56 days from cell injection), after i.p. injection of luciferin (150 pg/mouse).
- Figure 16 shows the antitumor effect of ST8154AA1 (24) in comparison with Ce- tuximab (Ctx) and ST7612AA1 against an orthotopic tumor pancreas.
- Figure 17 shows the antitumor activity of ST8154AA1 (24) in comparison with Ce- tuximab delivered intrapentoneally (q4dx5) against a patient-derived tumor xenograft (PDX) pancreas carcinoma implanted sc in nude mice.
- NOD SCID mice received sc tumor cells (51000 cells) from a patient PA5363.
- Figure 21 shows the antitumor activity of ST8176AA1 (28) in comparison with Trastuzumab delivered intraperitoneally according to the schedule q4dx4 against LS174-T colon carcinoma.
- Tumors were allowed to develop in Nu/Nu mice after i.p. injection of 10x10 6 LS174T colon cancer cells.
- Figure 23 shows the antitumor activity of ST8176AA1 (28) in comparison with Trastuzumab delivered intraperitoneally according to the schedule q4dx4 against a PDX (patient-derived xenograft) pancreas cancer.
- Human pancreas tumor cells (77x10 3 ) from the patient PA5363 were sc injected in NOD-SCID mice.
- the invention relates to novel ADCs made of anti-cancer antibodies conjugated to HDACi-based payloads.
- Such ADCs are shown to specifically bind tumor receptors, to be internalized and delivered to lysosomes. These properties surprisingly correlate with in vitro cytotoxicity and in vivo antitumor activities despite the low potency of the HDAC payloads.
- the antibody-drug-conjugates of the invention are particularly useful in the treatment of tumors or any other diseases where a modulation of one or more histone deacetylase isoforms and the expression of ErbB receptors are effective for therapeutic intervention.
- the present invention describes safe and efficacy ADC comprising a safe HDACi conjugated with a linker to an antibody and in particular an immunoglobulin used for cancer treatment.
- the epigenetic modulator, HDAC inhibitor allows ADC construction with reduced negative and toxic effects.
- a preferred embodiment of the present invention is the use of HDACi-based ADCs for the therapy of cancer expressing receptors such as ErbB1 , ErbB2 or ErbB3 including as example, lung, breast, colon, brain, head and neck, endometrial, renal, pancreatic, gastric, oesophageal, ovarian and prostate cancer and leukaemia.
- the present invention relates to antibody-drug-conjugates of Formula (I)
- D is a cytotoxic drug (also referred to as warhead), is a histone deacetylase inhibitor drug that contains benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG),
- CU is a connecting unit, which may be absent or which is selected from
- L is a linker, which is selected from (CH 2 )q-CO, NH-(CH 2 )r-(PEG)s-(CH 2 )w-CO, NH-CO-(CH 2 )r-(PEG)s-X-(CH 2 )w-CO, wherein X may be absent, NH or O, q is an integer of 2 to 8, r may be absent or is an integer of 1 to 4, s may be absent or is an integer of 1 to 6, and w may be absent or is an integer of 1 to 2,
- S2 is a spacer and may be absent or is
- CG is a connecting group fornned after conjugation to the cysteine thiol- or lysine amino- groups of the antibodies, which can be absent or one of following moieties:
- y is an integer of 0 to 8.
- Ab is an antibody or an antigen binding fragment thereof, and m, n, o and p represent integers of 0 or 1 .
- the linker (L) is preferably selected from
- n is an integer of 2 to 5
- a payload is a toxin (HDAC inhibitor) linked to a suitable linker / spacer, which ends with groups (i.e., maleinnide, NHS esters) suitable for conjugation to antibodies and comprises the following part of formula I:
- (CG) in the payloads of Formula II may be NHS (N- Hydroxysuccinimide) or an activated acylderivative (including pentaflurophenyl ester, p-nitro and 2,4-dinitrophenol ester, thiophenol ester, acylimidazole, isobutyl- carbonate, trichlorobenzoic anhydride), or maleimide- or 3-methylenesuccinimide, 3,4-dibromo maleimide or ⁇ amino-carbonyl ⁇ -3-butenoic acid of the following formulae:
- the histone deacetylase inhibitor (HDAC) used in the payload D-(CU) m -(S1 )n-L- (S2) 0 -(CG)p- may be a histone deacetylase inhibitor known in the art, and be of the following categories:
- Thiol-based histone deacetylase inhibitors such as ST7464AA1 and ST7660AA1 (a thiol analogue of vorinostat), having the following formulas:
- HDACs Hydroxamic acid based histone deacetylase inhibitors
- SAHA vorinostat
- LH589 panobinostat
- LAQ824 dacinostat
- HDACs histone deacetylase inhibitors
- MS275 entinostat
- CS055 chidamide
- the histone deacetylase inhibitor is ST7464AA1 , drug of corresponding prodrug ST7612AA1 , an oral thiol-based histone deacetylase inhibitor.
- the payload comprises a "leaving group”, which refers to a group that can be substituted by another group in a substitution reaction.
- leaving groups are well- known in the art and examples include, but are not limited to, halides (fluoride, chloride, bromide and iodide), azides, sulfonates (e.g., an optionally substituted C1 -C6 alkanesulfonate, such as ethanesulfonate and trifluoromeethanesulfonate, or an optionally substituted C7-C12 alkylbenzenesulfonate, such as - toluenesulfonate), succinimide-N-oxide, p-nitrophenoxide, pentafluorophenoxide, tetrafluorophenoxide, arboxylates, aminocarboxylates (carbamates) and alkoxycarboxylates (carbonates).
- halides and sulfonates are preferred leaving groups.
- a halide succinimide-N-oxide, p-nitrophenoxide, pentafluorophenoxide, tetrafluor- ophenoxide, a carboxylate, or an alkoxycarboxylate (carbonate) may for example be used as a leaving group.
- the term "leaving group” also refers to a group that is eliminated as a consequence of an elimination reaction, e.g., an electronic cascade reaction or a pirocyclization reaction.
- a halide, a sulfonate, an azide, an aminocarboxylate (carbamate) or an alkoxycarboxylate (carbonate) may for example be used as a leaving group.
- the histone deacetlyase inhibitor is the compound ST7612AA1 being a prodrug of the compound ST7464AA1 as shown above.
- Payloads with a specific linker containing N- hydroxysuccinimide (NHS) moiety are able to co- valently bound, through an amide bond, to the side chain of a Lys residue of mAbs that contains an amino-specific NHS ester may that reacts with antibody lysines.
- Payloads with a specific linker containing maleimide moiety i.e. ST8152AA1 , ST8189AA1
- the antibody-drug-conjugates differ from the payloads for the connective group (CG) where, in the payloads (CG)' it was NHS or Maleimide while in the antibody conjugates, (CG) is absent, in the NHS payload-based ADCs, while it is a succinimidyl moiety in Maleimide payload-based ADCs.
- the spacer (S1 ), if it is present, may be deavable or non-cleavable.
- a typical protease-cleavable spacer contain a moiety characterize by a fast enzymatic release of the drug in the target cell, such as the valine-citrulline (Val-Cit) dipep- tide.
- non-cleavable spacer examples include
- the claimed antibody drug conjugates may further contain a linker (L), which may be (CH 2 )q-CO, NH-(CH 2 )r-(PEG)s-(CH 2 )w-CO, NH-CO-(CH 2 )r-(PEG)s-X-(CH 2 )w- CO, where X may be absent, NH, O, q is 2-8, r is absent or 1 -4, s is absent or 1 -6, and w is absent or 1 -2
- L linker
- the claimed antibody-drug-conjugates may further contain a connecting group (CG) formed after conjugation to the cysteine thiol- or lysine amino- groups of the antibodies, which can be absent or one of following moiety: NHS or an activated acylderivative (including 1 -hydroxybenzotriazole ester, ethyl 2-cyano-2- (hydroximino) acetate ester, N-ethoxycarbonyl-2-ethoxy-1 ,2-dihydro-quinolone ester, pentaflurophenyl ester, p-nitro and 2,4-dinitrophenol ester, thiophenol ester, acylimidazole, isobutylcarbonate, trichlorobenzoic anhydride, pivalic anhydride, 3,5-dimethoxytriazine) or maleimide- or 3-methylenesuccinimide, 3,4-dibromo ma- leimide or ⁇ amino-carbonyl ⁇ -3-but
- the immunoglobulin vectors herein described are directed against receptors of the tyrosine kinase (RTK) family. This is a superfamily of transmembrane proteins that mediate intracellular signaling by phosphorylating substrate proteins involved in cell proliferation, survival, differentiation or migration.
- RTK tyrosine kinase
- the Human Epidermal growth factor Receptor (HER) family belongs to the RTKs superfamily, and comprises four members: ErbB1/EGFR (epidermal growth factor receptor), ErbB2, ErbB3 and ErbB4. Physiologically, these receptors are activated by the ligands of the EGF family.
- EGFR plays a causal role in the development and maintenance of many human carcinomas, with mutation and overexpression observed in a number of tumor types (Burgess AW 2008 Growth Factors 26: 263-74).
- EGFR has become a clinically validated target for antibodies as well as for tyrosine kinase inhibitors having gained widespread use in lung, head and neck, colon, and pancreatic cancers (Mendelsohn J 2006 Semin Oncol 33: 369-85; Feiner 2016 Exp Rev Proteomics, Sep 13: 817-32; Encher AA 2012 Front Biosci 4: 12- 22; Landi L 2014 Expert Opin Pharmacol Ther 15: 2293-305).
- a microtubule inhibitor-based ADC targeting EGFR is a questionable therapeutic strategy in that it may improve the activity of anti-EGFR antibodies by circumventing resistance mediated by downstream signaling mutations, but, because of the known toxicity of these antibodies (i.e. skin rash, diarrhea, constipation, stomatitis, fatigue, and electrolyte disturbances) (Li T 2009 Target Oncol 4: 107-19) it might have limited applicability. It was surprisingly found that ADCs made of anti-EGFR family protein antibodies conjugated to low toxicity HDACi are effective anti-cancer agents.
- the antibody used in the claimed antibody-drug-conjugate is particularly an antibody directed against an EGFR family protein.
- the antibody may be directed to the ErbB1 , ErbB2 or ErbB3 receptors.
- the same payloads conjugated to other antibodies can be directed against other receptors internalized by tumor cells to release the HDACi.
- c-Met implicated in the growth, survival and spread of various human cancers and overexpressed in different solid tumors is internalized in response to HGF (hepatocyte growth factor) binding, leading to c- Met ubiquitination and degradation (Mellman 2013 Cold Spring Harb Perspect Biol 5:a016949).
- HGF hepatocyte growth factor
- the antibody is selected from Trastuzumab, Cetuximab, Bevacizumab, Panitumumab, anti-CD4, or anti-CD30 antibodies, and related bio- similar antibodies.
- antibody or immunoglobulin may be used interchangeably in the broader sense and include monoclonal antibodies, polyclonal antibodies, isolated, engineered or recombinant antibodies, full-length or intact antibodies, multivalent or multispecific antibodies such as bispecific antibodies or antibody fragments thereof as long as they exhibit the desired biological activity.
- a recombinant antibody which is the result of the expression of recombinant DNA within living cells
- the antibody may be derived from any species and is preferably derived from humans, rats, mice and rabbits. If the antibody is derived from a species other than a human species, it is preferably a chimeric or humanized antibody prepared according to techniques well-known in the art.
- the antibody may also be a chemically synthesized antibody.
- the antibody can target the cancer or tumour cells in question, in particular cancer or tumor cells expressing ErbB1 , ErbB2 and/or ErbB3 receptors.
- the antibody has the property of recognizing said cancer or tumor cells, has a property of binding to said cancer or tumor cells and a property of internalizing into a tumor or a cancer cell.
- an antigen-binding fragment can also be used which indicates any peptide, polypeptide or protein retaining the ability to bind to the target (antigen) of the antibody.
- antigen-binding fragments are Fv, ScFv (Sc means single-chain), Fab, F(ab')2, Fab', ScFv', Fc fragments or Diabodies or fragments the half-life of which has been increased by a chemical modification, such as, for example, pegylation or by incorporation into a liposome.
- ADC antibody drug conjugate
- pharmaceutically ceptable salt thereof are selected by the compounds having the formulae:
- the active drug (D) is represented by ST7464AA1 that corresponds to the active drug of ST7612AA1 .
- ST7464AA1 is one of the possible drugs (D) of ADCs (Formula I) and of payloads (Formula II), described in the present invention.
- H unoglobulin mAb, Fab
- ADCs Antibody Drug Conjugates
- ADCs Antibody Drug Conjugates
- a spacer (S1 ) - that can be cleavable normally the valine-citrulline dipeptide (Val-Cit), substrate of enzyme cathepsin
- CG terminal group
- ADCs Antibody Drug Conjugates
- ADCs which normally consists of a conjugation reaction between the residue (CG)' of the payload part of the molecule and an amino group of a lysine residue of the immunoglobulin (Ab).
- cysteines the S-S cystine bonds of the immunoglobulin have to preliminarily be reduced with an appropriate reducing agent.
- -SH sulfhydryl groups
- SoC Site of Conjugation
- Said pharmaceutical compositions contain at least an excipient and/or a pharmaceutically acceptable vehicle.
- the active ingredient can be administered in unit form of administration in admixture with conventional pharmaceutical carriers to animals or to human beings.
- Suitable unit forms of administration comprise forms for enteral or parenteral administration, wherein the enteral administration comprises oral, aerosol, rectal or buccal route, and parenteral administration comprises subcutaneous, intramuscular or intravenous, and intradermic route.
- composition may be for enteral or parenteral administration, wherein the enteral administration comprises oral, aerosol, rectal or buccal route, and parenteral administration comprises endovenous, intramuscolar, and intradermic route.
- a solid composition for oral administration can be a tablet, a pill, a powder, a capsule or a granulate.
- the antibody-drug-conjugate of the invention is mixed with one or more inert diluent such as starch, cellulose, sucrose, lactose or silica.
- these compositions may also comprise further substances, such as lubricants, such as magnesium stearate or talc or coloring agents or coating agents.
- a sterile composition for parenteral administration may preferably be an aqueous or non-aqueous solution, suspension or emulsion.
- a solvent or vehicle used can be made of water, propylene glycol or polyethylene glycol, vegetable oils, injectable organic esters or other suitable organic solvents. These compositions may also contain adjuvants, in particular wetting, isotonic, emulsifying, dispersing and stabilizing agents.
- the present invention reports in vitro cell proliferation assay at demonstration of the efficacy provided by the new ADCs.
- a particular embodiment of the invention is a formulation suitable for local delivery by nebulization.
- the antibody-drug-conjugates of the invention are particularly suitable in the treatment of diseases associated with the lung or the peritoneum such as lung or peritoneal cancer or cancer from ovarian, cervix- endometrium, gastric, colon, appendiceal, pseudomyxoma peritonei, pancreas, liver metastases, rare neoplasie (abdominal sarcoma of not gut tissues).
- the present invention also provides a compound of formula (I) as defined above, for use in a method of treating cancer, cellular proliferation disorders and viral infections.
- a compound of formula (I) as defined above is for use in a method of treating specific types of cancers, such as but not limited to: carcinomas, including bladder, breast, colon, kidney, liver, lung, comprising small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin carcinoma, comprising squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; tumor
- the present invention reports in vitro cell proliferation assay at demonstration of the efficacy provided by the new ADCs.
- the compounds of the invention bind to the receptor in a comparable manner to that of the free antibodies and the binding of the ADCs to ErbB1 -and ErbB2- expressing tumour cell was confirmed by FACS analysis.
- the compounds of the invention are able to internalize with tumour cells in a comparable manner to their native counterpart antibodies without any reduction in the binding rate.
- all the ADCs of the invention react with their specific receptor with potency comparable to that of a native antibodies bound to the ADC, as for example Cetux- imab or Trastuzumab.
- the ADCs of the invention maintain their integrity when nebulized and thereof they can be comprised in composition for nebulization, which represent a powerful method for deliver mAbs in respiratory diseases.
- This method is a non-invasive method suitable for targeting drugs to the lungs, limiting the exposure to secondary organs.
- the compounds of the invention inhibit tumour cell proliferation with IC50 values lower than those of cetuximab alone, when evaluated on lung adenocarcinoma cells, thus confirming their antitumor efficacy.
- the new ADCs show an antitumor activity by aerosol delivery and intraperitoneal route on a local tumour, useful for pressurized intraperitoneal aerosol chemotherapy (PIPAC).
- PIPAC pressurized intraperitoneal aerosol chemotherapy
- N2 compound [8] (87 mg, 0.11 mmol) is dissolved in a mixture of tetrahydrofuran / dimethylformamide 3:1 (4 ml_) at 0° C. Then N-(2- aminoethyl)maleinnide trifluoroacetate salt (33 mg, 0.13 mmol), 1 - hydroxybenzotriazole hydrate (22 mg, 0.16 mmol), HBTU (61 mg, 0.16 mmol) and ⁇ /,/V-diisopropylethylamine (0.048 mL, 0.27 mmol) are added and the mixture kept at 0° C for 30 minutes, and then at room temperature for 16 hours.
- the reaction mixture is diluted with dichloromethane and washed two times with water and two times with brine, dried over anhydrous sodium sulfate and the solvent removed by rotatory evaporation.
- the residue is purified by flash column chromatography 2- 20% methanol in dichloromethane.
- the product ST8152AA1 is obtained as a colorless viscous liquid, 55 mg (60% yield). MS: m/z 859 [M+Na] + .
- EEDQ (31 1 mg, 1 .26 mmol) is added to a solution of compound [15] (240 mg, 0.63 mmol) and monoethyl pimelate [16] (0.123 ml_, 0.69 mmol) in a mixture of di- chloromethane/methanol 2:1 (20 ml_).
- the reaction is left in the dark at room temperature for 12 hours.
- the solvents are removed and the residue purified by column chromatography 2-20% methanol in dichloromethane to give product [17] as a viscous solid, 170 mg (45% yield).
- ST7612AA1 (125 mg, 0.31 mmol) is dissolved in degassed methanol (8mL) in a 50 mL flask under N2 atmosphere.
- a solution of sodium thiomethylate 1 M in degassed methanol (22 mg, 0.31 mmol) is added at room temperature to the first solution.
- the stirring mixture is maintained at room temperature for 30 minutes.
- the solution is flushed with N2 for 5-10 minutes to eliminate MeSH, then the solvent is removed by rotatory evaporation.
- Compound [18] (170 mg, 0.31 mmol) dissolved in a minimum amount of anhydrous dimethylformamide is added to the residue and the mixture kept at room temperature for 16 hours.
- Lithium hydroxide monohydrate (42 mg, 1 mmol) is added to a solution of [19] (300 mg, 0.33 mmol) in a mixture of tetrahydrofuran/water/ethanol 1 :1 :1 (12 mL). The reaction is kept at room temperature for 6 hours, then it is diluted with ethyl acetate and washed with HCI 1 N. The crude (180 mg) is directly used for the next step without any purification. MS: m/z 874 [M+Li] + ; 890 [M+Na] + .
- the para-nitro derivative (501 mg, 1 mmol) and DBU (1 .5 ml, 10 mmol) are dissolved in CH2CI2 and /V-(2-aminoethyl)maleinnide trifluoroacetate (254 mg, 1 mmol) is added.
- the reaction mixture is stirred at room temperature overnight.
- the solution is then diluted with CH2CI2 (25 ml_) washed with 1 N HCI (3 x 10 ml_) and brine (20 ml_) and dried over Na2SO 4 dry.
- the azido derivative obtained (49 mg, 0.10 mmol) is dissolved in dry THF (10 mL) at 0 °C.
- Triphenyl phosphine (53 g, 0.2 mmol) is added and the mixture is stirred for 24 h at room temperature.
- H2O (5 mL) is then added to hydrolyse the intermediate phosphorus adducts and the solution is stirred for another 24 h at room temperature.
- THF is evaporated and the solid residue is suspended in water (10 mL).
- the white solid is filtered with dichloromethane to remove the dicyclohexylurea, the organic phase is washed with HCI 0.1 N and H2O, then dried over dry sodium sulfate and the solvent removed under reduced pressure.
- the resulting residue is purified by flash column chromatography to give the activated acid as a white waxy material (yield 90%) that is dissolved into dimethoxyethane (5 mL) and treated with 20-amino- 3,6,9, 12, 15, 18-hexaoxaicosanoic acid (46 mg, 0.1 mmol) dissolved in a mixture of tetrahydrofuran and aqueous sodium bicarbonate (15 mg, 0.15 mmol in 2 mL of water).
- Acetyl chloride (1 .01 mL, 14.26 mmol) is added to a solution of acid [7] (1 .00 g, 2.85 mmol) in MeOH (50 mL) in a round bottom flask under N2. The resulting solution is stirred at room temperature for 3 h, and then the solution is concentrated in vacuo. The residue is dissolved in CH2CI2 (30 mL) and washed with a saturated solution of aqueous sodium bicarbonate (3 x 15 mL) and brine (2 x15 mL). The organic phase is dried over sodium sulfate, filtered and concentrated in vacuo to provide 950 mg (2.61 mmol) of compound [27] as a white solid (yield 92%).
- PBr 3 (28 ⁇ _, 0.30 mmol) is added at 0 °C to a solution of alcohol [28] (100 mg, 0.20 mmol) in THF dry (5 mL) in a round bottom flask under an atmosphere of N2.
- the resulting solution is stirred at 0 °C for 2 h and then allowed to warm to room temperature; after the addition of CH2CI2 (1 mL) the solution turns orange and is concentrated in vacuo.
- the crude reaction mixture is purified by silica gel flash chromatography (EtOAc 100%) to provide 78 mg (0.14 mmol) of compound [29] as a bright orange oil (yield 70%).
- bromide [29] (78 mg, 0.14 mmol), SAHA (50 mg, 0.18 mmol) and 1 ml_ of DMF dry are mixed at room temperature.
- Freshly distilled DIPEA (45 mg, 0.36 mmol) is added dropwise and the solution is stirred at room temperature for 12 h.
- the solvent is then removed via rotator evaporation and high vacuum.
- the residue is purified by flash column chromatography with a gradient 0- 20% methanol in dichloromethane to provide the product [30] as a white solid 48 mg, 45% of yield.
- Lithium hydroxide monohydrate (8 mg, 0,18 mmol) is added to a solution of [30] (48 mg, 0.063 mmol) in a mixture of tetrahydrofuran/water/ethanol 1 :1 :1 (6 ml_). The reaction is kept at room temperature for 2 hours, then it is diluted with ethyl acetate and washed with HCI 1 N. The crude (25 mg) is directly used for the next step without any purification.
- bromide [18] 60 mg, 0.09 mmol
- SAHA 28 mg, 0.10 mmol
- 1 mL of DMF dry are mixed at room temperature.
- Freshly distilled DIPEA 25 mg, 0.20 mmol
- the solvent is then removed via rotator evaporation and high vacuum.
- the residue is purified by flash column chromatography with a gradient 0- 20% methanol in dichloromethane to provide the product [31 ] as a white solid 48 mg, 68% of yield.
- Lithium hydroxide monohydrate (8 mg, 0,18 mmol) is added to a solution of 40 (48 mg, 0.06 mmol) in a mixture of tetrahydrofuran/water/ethanol 1 :1 :1 (6 ml_). The reaction is kept at room temperature for 6 hours, then diluted with ethyl acetate and washed with HCI 1 N. The crude (25 mg) is used for the next step without any purification. MS: m/z 765.7 [M-H] ⁇ .
- Dicyclocarbodiimide (1 1 mg, 0.05 mmol) and N- hydroxysuccinimide (6 mg, 0.045 mmol) are added at room temperature to a stirrer solution of the crude product previously obtained (25 mg, 0.03 mmol) in DMF dry (0,80 ml_). The mixture is kept at room temperature for 16 hours.
- the white solid formed in this reaction is filtered with dichloromethane to remove the dicylohex- ylurea, the organic phase washed with HCI 0.1 N and water, then dried over anhydrous sodium sulfate and the solvent removed by rotatory evaporation.
- N-Phenyl-7-sulfanyl-heptanamide (ST7660AA1) (60 mg, 0.25 mmol) is suspended in degassed methanol (1 ml_); compound [7] (84 mg, 0.24 mmol) is added at room temperature to the stirring mixture and after some minutes it becomes a clear solution. The solution is kept under stirring at room temperature for 20 hours till TLC monitoring shows complete conversion of [7]. The solvent is then removed by rotatory evaporation and the raw material is purified by column chromatography in gradient 2-10% methanol in dichloromethane. The compound [33] is obtained as a white solid, 1 15 mg (81 % yield). MS: m/z 610 [M+Na] + .
- 6-Azidohexanoic acid [40]: 6-Bromohexanoic acid (200 mg, 1 ,02 mmol) and sodium azide (333 mg, 5,12 mmol) in 5 mL of dimethylformamide are heated at 100 °C for 16 hours in sealed vial. After cooling, the reaction is diluted with ethyl acetate and washed with KHSO 4 1 M, H2O and brine. The organic layer is collected and dried over anhydrous sodium sulfate, and the solvent removed by rotatory evaporation.
- the mixture is kept at room temperature for 16 hours.
- the white solid formed in this reaction is filtrated with dichloromethane and the organic phase washed with water, then dried over anhydrous sodium sulfate, filtered and the solvent removed by rotatory evaporation.
- Example 12 A general synthetic procedure for panobinostat- and dacino- stat-based payloads.
- Example 13 Synthesis and characterization of ADCs by conjugation to ⁇ - amino groups of lysine residues to N-Hydroxysuccinimide (NHS).
- ADCs made of HDAC is conjugated to four different antibodies (Trastuzumab Herceptin® Roche; Cetuximab Erbitux® Merck; Bevaci- Kursab Avastin® Genentech/Roche; Panitumumab Vectibix® Amgen) and two mouse anti-human CD4 antibodies commercially available, the clone SK3 (also known as Leu3a) and the clone RPA-T4.
- the approved antibodies are Trastuzumab recognizing ErbB2, Cetuximab and Panitumumab recognizing ErbB1 , Bevacizumab recognizing VEGFR.
- Antibodies were buffer exchanged using a 10 kDa cut-off dialysis membrane to yield antibodies solution in PBS pH 7.4 and to remove interfering preservative. The concentration after dialysis was determined measuring the OD280 and - the ab- sorbance reading of the sample - was divided by 1 .36.
- a 10 mM of a stock solution contains an amine-reactive N-hydroxysuccinimide (NHS ester) payload was prepared in DMSO and a 20-fold molar excess of pay- load was added to each one of antibody solution. Reactions were incubated at room temperature, with gentle continuous mixing and after 1 hour, they were quenched adding a 20 mM glycine aqueous solution.
- NHS ester N-hydroxysuccinimide
- DARs Drug-Antibody Ratio
- MALDI mass spectrometry using an Ultraflex III mass spectrometer (Bruker, GmbH), operating in positive linear mode.
- a 10 mg/ml s-DHB MALDI matrix solution was prepared in 0.1 %TFA dissolved in H2O:ACN (50:50, v/v). 2 ⁇ of samples solution (antibodies or ADCs) were deposited on MALDI target using a double layer sample deposition method. The mass spectra were acquired in a mass to charge range starting from 50 kDa to 180 kDa.
- the mass difference between unconjugated and conjugated antibodies was used to determine the DAR.
- the antibodies Trastuzumab, Cetuximab, Panitumumab, Bevacizumab as well as the two anti-human CD4 antibodies were used for the conjugation reactions under the experimental conditions described above.
- Example 14 Synthesis and characterization of ADCs prepared by conjugation at the cysteine residue with maleimide-containing payloads.
- Antibodies were buffer exchanged using a 10 kDa cut-off dialysis membrane to yield antibodies solution in PBS pH 7.4 and to remove interfering preservative. The concentration after dialysis was determined measuring the OD280 and the absorb- ance reading of the sample was divided by 1 .36.
- TCEP is a thiol-free compound, removing the excess of the reducing was not necessary and a 20-fold molar excess of a 10 mM maleimide-based payload stock solution prepared in DMSO, was added to each one of reduced antibody solutions.
- DARs Drug-Antibody Ratio
- the mobile phase A was 1 .5 ammonium sulfate, 50mM sodium phosphate, pH 7 and isopropanol (95:5; v/v)
- the mobile phase B was 50mM sodium phosphate, pH 7 and isopropanol (80:20; v/v).
- the mobile phase A was maintained at 100% for 1 minute after the injection and then the mobile phase B was increased to 100% in 30 minutes and hold for 5 minutes.
- UV profiles were registered at 220 and 280 nm. All antibodies, such as Trastuzumab and Cetuximab, according to the present invention, were prepared by a process which involve conjugation reactions under the experimental conditions described above. ADCs with an average DAR ranging from 3.5 to 4.6 were obtained.
- Example 15 Determination of ADCs binding to ErbB1 and ErbB2 receptors on tumor cells
- Binding of the ADCs to ErbB1 - and ErbB2-expressing tumor cells was confirmed by FACS analysis.
- Various tumor cell lines with different levels of EGFR and ErbB2 expression including lung (A549, H1975), breast (SKBR3), colon (LS174T), ovarian (SKOV3), pancreas (CAPAN1 and MIAPACA-2) and stomach (N87) carcinoma cell lines, were used in the experiments.
- Cell pellets were incubated 1 hour, at 4°C, with 10 g/mL antibodies or ADCs in PBS and then, after two washings in PBS, stained 1 hour, at 4°C, with mouse anti-human FITC-conjugated IgGs (BD Pharmingen).
- ++ is a score representing a high extent of binding or internalization.
- ADCs ability of ADCs to internalize within tumour cells, following their binding to cognate receptors, was assessed by means of HCS fluorescence imaging, through Operetta system (Perkin Elmer).
- tumour cell types including lung (A549, H1975), breast (SKBR3), colon (LS174T), ovarian (SKOV3), pancreas (CAPAN1 ) and stomach (N87) carcinoma cell lines.
- Cells were seeded in 96-well mi- crotiter plates (0.5-1 x10 4 /well) and then incubated with 5 g/mL antibodies in culture medium, for 3 hours at 37°C.
- Example 17 Determination of the binding of ADCs on receptors by ELISA and Biacore
- Immunoreactivity of ADCs was tested by antigen-specific ELISA. Briefly, Immuno MAXISORP 96-well plates (Nunc) were coated overnight at 4°C with 50 ng/well of recombinant human EGF-R/ErbB1 Fc chimera (R&D) or recombinant Human ErbB2/HER2 protein (Sino Biological Inc.). After washing with PBS/0.1 % Tween (PT) solution, plates were blocked 2 hours at room temperature (RT) with PT solution containing 1 % BSA (PTB), and then incubated with serial dilutions of antibodies, 1 h at room temperature.
- RT room temperature
- PTB PT solution containing 1 % BSA
- HRP horseradish peroxidase
- Example 18 Determination of integrity of ADC after nebulization process.
- Nebulization has been recently shown to be a promising delivery method for mAbs in respiratory diseases, representing a non-invasive method suitable for targeting drugs directly to the lungs, limiting the exposure of secondary organs.
- the present inventors sought to assess by HPLC analysis the recovery and integrity of ADCs following nebulization. Briefly, 300 g/mL solutions (in PBS) of ADCs and their parental antibodies, cetuximab and trastuzumab, were nebulized for 5 minutes through a conventional jet nebuliser (AirFamily system, Pic indolor). Nebulized drugs were then collected by conveying the mist in falcon tubes and 100 ⁇ _ of condensed solution was analysed by SEC-HPLC (TSKgel G3000 SWXL column, TOSOH Bioscience) in comparison to pre-nebulized samples.
- SEC-HPLC TSKgel G3000 SWXL column, TOSOH Bioscience
- Percentage of recovery after nebulization was calculated by measuring the area of each relative peak with respect to pre-nebulized samples, and ranged from 50% to 30% and from 40% to 20% for ADCs in the case of cetuximab-based and trastuzumab-based ADCs, respectively. Integrity and aggregation incidence were also assessed for each nebulized ADC, according to the profile of each chromato- gram, and compared to those of not-nebulized samples (see Table 5).
- Example 19 Determination of the capacity of ADCs to inhibit tumor cell proliferation
- NCI-H1975 tumor cells are characterized by overexpression of double-mutant (L858R, T790M) ErbB1 gene, whereas Calu-3 express the wild type form of EGFR but mutant K-Ras (G13D) gene, as well as mutant TP53 and CDKN2A genes.
- Cells were seeded (at 3.000-5.000 cells/well) into 96-well plates in complete culture medium and then incubated for 6 days, in quadruplicate, with scalar concentrations of ADCs, ranging from 500 to 6.25 nM. Inhibition of cell proliferation was measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega), through a Veritas luminometer (Promega). Data were expressed as the average ( ⁇ SD) of percentage inhibition of two independent experiments. The IC50 values were ultimately calculated by using the GraphPad Prism 5.0 software.
- Results showed that ADC ST8154AA1 significantly inhibited tumor cell proliferation of both cell lines (with IC50 values of 250 nM and 450 nM, on NCI-H1975 and Calu-3 cells, respectively), as compared to cetuximab alone that, instead, was not effective (IC50>500 nM) ( Figures 6-7).
- Example 20 Determination of activity of ADCs on acetylation of histone H3 and oTubulin in tumor cells.
- ADCs acetylation of typical HDAC substrates, i.e. histone H3 and a-tubulin protein
- HCS fluorescence imaging was assessed by means of HCS fluorescence imaging on different tumor cells.
- Cells were seeded in 96-well microtiter plates (0.5- 1 x10 4 /well) in complete culture medium and, the day after, incubated with 5 g/mL antibodies or ADCs, for 3 or 24 hours at 37°C. Following two washings with PBS, cells were fixed with 4% formaldehyde in PBS, permeabilized with PBS 0.2%Tween-20 (PBS-T) and blocked with 2% BSA in PBS-T.
- Mouse anti- acetylated-a-tubulin IgG (clone 6-1 1 B-1 , from Sigma Aldrich) or rabbit anti- acetylated-histone H3 IgG (from Active Motif) were then added in PBS-T, and cells were incubated 1 hour at room temperature. After two washings with PBS, cells were ultimately stained for 1 additional hour with FITC-conjugated goat anti-mouse or anti-rabbit IgG (BD Pharmingen), according to the primary antibody used. Fluorescence was acquired and analyzed by means of the High Content Screening (HCS) system Operetta (Perkin Elmer). Cells were counterstained with Draq5 dye (Cell Signaling).
- HCS High Content Screening
- Nonspecific binding sites were then blocked by incubation of the membranes with 5% non-fat dry milk in TBS, overnight at 4 °C.
- Specific primary antibodies (rabbit anti-acetyl-histone H4 antibody, from Santa Cruz; mouse anti-histone H4 monoclonal antibody, from Cell Signaling; mouse anti-acetylated a-tubulin monoclonal antibody, from Sigma Al- drich, rabbit anti-a-tubulin antibody, from abeam), were added to the membranes at the optimal dilution in 5% nonfat dry milk/TBST overnight at 4 °C. Following four washes in TBST, membranes were incubated for 1 h with HRP-conjugated secondary antibodies in 5% non-fat dry milk/TBST. Immunoreactive bands were finally visualized by enhanced chemiluminescence with the ECLplus Western blotting detection reagent (GE Healthcare), and analyzed by a phosphoimaging system (STORM, Molecular Dynamics). Representative blots are shown in Figure
- Example 21 Determination of in vivo antitumor effect of ST8154AA1 and ST8155AA1 given ip against NCI-H1975 non-small cell lung cancer
- Example 22 Determination of in vivo antitumor effect of ST8154AA1 given ip against A549 non-small cell lung cancer.
- Nude mice were given a subcutaneous injection of 5x10 6 A549 non-small cell lung carcinoma cells suspended in 100 ⁇ _ cell culture medium RPMI supplemented with 10% FBS.
- Cetuximab and ST8154AA1 were administered intraperitoneally every 4 days for 4 days (q4dx4) at a dose of 50 mg/ kg. Tumor measurements and data as in Example 21 .
- Example 23 Determination of in vivo antitumor effect of ST8154AA1 delivered by aerosol against metastatic A549 non-small cell lung cancer.
- Metastatic lung cancer was established by injecting 5x10 6 A549-luc-C8 (A549luc) cells into the tail vein of immunodeficient SCID/beige mice. After 1 week the mice were randomized and treated by whole body aerosol (by means of the AirFamily system, Pic indolor) with ADC or Cetuximab (3.5 ml_ of 100 pg/nriL solution). Treatments were repeated according to the schedule q7dx4. Tumor biolumines- cence imaging (BLI) was recorded at different time points by Xenogen MS Imaging System 200 (Perkin Elmer), 15 min after i.p. injection of luciferin (150 pg/mouse). The evaluation of bioluminescence showed that ADC was able to significantly inhibit tumor metastases with a higher potency in comparison with Cetuximab and at different times of tumor collection (P ⁇ 0.01 and P ⁇ 0.05) ( Figure 15, Table 7).
- Example 24 Determination of in vivo antitumor effect of ST8154AA1 delivered ip against CAPAN-1 pancreas cancer
- ST8154AA1 showed to inhibit the tumor growth of 84% with 6 out 10 mice with complete responses, while Cetuximab gave 49% of tumor growth inhibition with 2 out 10 mice with complete responses.
- ST7612AA1 alone showed a lower activity on tumor growth (32%), because q4dx4 is not the optimal schedule for am HDAC inhibitor.
- Tumor weight was evaluated 90 days after tumor injection and expressed as mean and SEM, P ⁇ 0.05 vs Ctx) ( Figure 16, Table 7).
- Example 25 Determination of in vivo antitumor effect of ST8154AA1 delivered ip against a PDX (patient-derived xenograft) pancreas cancer
- NOD-SCID mice from Jackson Laboratories were given a single subcutaneous injection of cells of the patient PA5363 P2 at 51000 cells/100 ⁇ _ re-suspended in an equal volume of Cultrex 10x spheroid phormation ECM.
- Cetuximab and ST8154AA1 were administered intraperitoneally every 4 days for 5 days (q4dx5) at a dose of 40 mg/10 mL/kg. Tumor growth measurements and data as in Example 20.
- Example 26 Determination of in vivo antitumor effect of ST8178AA1 and ST8176AA1 given ip against SKOV-3 ovarian cancer
- mice from Charles River, Italy were given a single subcutaneous injection of 5x10 6 SKOV-3 ovarian carcinoma cells suspended in 100 ⁇ cell culture medium RPMI supplemented with 10% FBS. Mice for each experimental group were treated ip every four days, for 4 treatments (q4dx4), at a dose of 15 mg/10 mL/kg. Results showed that ST8178AA1 and ST8176AA1 were significantly more efficacious than Trastuzumab (P ⁇ 0.05) ( Figures 18-19, Tables 8 and 9). Tumor measurements and data as in Example 20. These data suggest a double effect of the ADC in comparison with Trastuzumab on the tumor growth.
- Example 27 Determination of in vivo antitumor effect of ST8176AA1 given ip against an orthotopically implanted SKOV-3 ovarian cancer
- Nude Nu/Nu female mice (from Charles River, Italy) were given a single intraperi- toneally injection of 10x10 6 SKOV-3 ovarian carcinoma cells suspended in 200 ⁇ _ cell culture medium RPMI supplemented with 10% FBS.
- mice were injected i.p. with either ST8176AA1 , Trastuzumab (4 doses of 15 mg/kg once every 4 days) or vehicle (PBS) starting 3 days after tumor injection. Either Trastuzumab or ST8176AA1 were efficacious but the ADC also showed 4 out 9 mice cured after 90 days from tumor implantation ( Figure 20, Table 9).
- Example 28 Detemination of in vivo anti-tumor efficacy of ST8176AA1 given ip against an intraperitoneal LS174-T colon cancer
- the ADCs were also evaluated against an intraperitoneal tumor such as colon carcinoma, an aggressive tumor xenograft model.
- ADCs may be also used by a local administration to treat diseases like peritoneal carcinomatosis.
- LS-174T colon cancer cells were injected ip. The cells were collected and washed two times with PBS. Ten million cells were suspended in 0.2 ml_ of EMEM medium containing 20% of MatrigelTM and injected in the peritoneum of each mouse. All the treatments with the ADC were performed by i.p. injection at a volume of 200 ⁇ _ 3 days post tumor injection, according to the schedule q4dx4.
- mice were monitored for mortality daily, while weight was recorded two times per week. Animals showing signs of discomfort, distress or in moribund condition were examined by the staff veterinarian or authorized personnel and, when necessary, humanely sacrificed to minimize undue pain or suffering.
- Mortality data were processed according to the most appropriate statistical analysis to determine increase life span among the treatments and to produce a Kaplan- Mayer plot. All the statistical analysis was performed using the software GraphPad-Prism6. The results showed a median survival time (MST) of 37 days in both vehicle- and Trastuzumab-treated groups. By contrast the ADC ST8176AA1 revealed to significantly increase the median survival time to 50 days (P ⁇ 0.05) ( Figure 21 , Table 9).
- PIPAC pressurized intraperitoneal aerosol chemotherapy
- novel ADCs show an antitumor activity by aerosol and intraperitone- ally on a local tumor, these data encourage to PIPAC use of the ADCs herein described in addition to the standard parenteral administration.
- PIPAC pressurized intraperitoneal aerosol chemotherapy
- Example 29 Determination of in vivo antitumor effect of ST8176AA1 given ip against LS-174T colon cancer
- mice were allowed to develop in Nu/Nu mice for 6 days after s.c. injection of 5x10 6 LS174T colon carcinoma cells. Lesion development and response to antibody treatment was monitored using a digital caliper. Mice were injected i.p. with either ST8176AA1 , Trastuzumab (4 doses of 15 mg/kg once every 4 days) or vehicle (PBS). The ADC ST8176AA1 revealed to significantly inhibit the tumor growth of colon cancer (P ⁇ 0.05 vs Trastuzumab) ( Figure 22, Table 9).
- Example 30 Dermination of in vivo antitumor activity of ST8176AA1 delivered ip against a PDX pancreas cancer
- NOD-SCID mice from Jackson Laboratories were given a single subcutaneous injection of cells of the patient PA5363 P2 at 77000 cells/100 ⁇ resuspended in an equal volume of Cultrex 10x spheroid phormation ECM.
- Trastuzumab and ST8176AA1 were administered intraperitoneally every 4 days for 5 days (q4dx5) at a dose of 15 mg/ /kg in experimental groups of 10 mice for each group. Tumor measurements and data as in Example 20.
- Example 31 Determination of in vivo antitumor effect of the combination of Cetuximab with a low dose of ST7612AA1 , corresponding to the loaded dose to mAb, against A549 lung cancer
- the anti-tumor effect of the ADC ST8154AA1 in comparison with the equimolar combination or Cetuximab and ST7612AA1 was also assessed against a model of A549 non-small cell lung carcinoma. Optimal doses of ST7612AA1 or Cetuximab were also investigated.
- mice/group The human A549 lung carcinoma cells were cultured in their appropriate complete medium. On the day of tumor injection, cells were harvested from subconfluent cultures by trypsinization, washed with PBS, suspended in PBS and subcutane- ously injected into the right flank of immunodeficient mice (5x10 6 /100 ⁇ _). Treatments started when tumor size was around 80 mm 3 and mice were randomized into the experimental groups (10 mice/group):
- cetuximab alone (40 mg/kg, ip, q4dx4) did not show any antitumor activity.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201909898A UA125311C2 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
JP2019553113A JP2020515578A (en) | 2017-03-27 | 2018-03-27 | HDAC Inhibitor Antibody Drug Conjugate (ADC) and Use in Therapy |
SG11201906543RA SG11201906543RA (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
CA3047359A CA3047359A1 (en) | 2017-03-27 | 2018-03-27 | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy |
CN201880022128.4A CN110475572A (en) | 2017-03-27 | 2018-03-27 | Antibody drug conjugate (ADC) based on hdac inhibitor and the purposes in therapy |
BR112019013449A BR112019013449A2 (en) | 2017-03-27 | 2018-03-27 | antibody conjugates (adcs) based on hdac inhibitors and use ms therapy |
TNP/2019/000187A TN2019000187A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
EA201991985A EA201991985A1 (en) | 2017-03-27 | 2018-03-27 | CONJUGATES ANTIBODY-MEDICINAL PRODUCT (KALS) BASED ON GDAC INHIBITORS AND USE IN THERAPY |
KR1020197028286A KR20190126824A (en) | 2017-03-27 | 2018-03-27 | HDAC inhibitor-based antibody drug conjugates (ADCs) and therapeutic uses |
US16/492,355 US20210128740A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
MX2019011492A MX2019011492A (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY. |
EP18712246.0A EP3600444A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
AU2018241840A AU2018241840A1 (en) | 2017-03-27 | 2018-03-27 | HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy |
IL26882119A IL268821A (en) | 2017-03-27 | 2019-08-21 | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
EP17163065.0 | 2017-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018178060A1 true WO2018178060A1 (en) | 2018-10-04 |
Family
ID=58448395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/057744 WO2018178060A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210128740A1 (en) |
EP (2) | EP3381474A1 (en) |
JP (1) | JP2020515578A (en) |
KR (1) | KR20190126824A (en) |
CN (1) | CN110475572A (en) |
AU (1) | AU2018241840A1 (en) |
BR (1) | BR112019013449A2 (en) |
CA (1) | CA3047359A1 (en) |
EA (1) | EA201991985A1 (en) |
IL (1) | IL268821A (en) |
MX (1) | MX2019011492A (en) |
SG (2) | SG11201906543RA (en) |
TN (1) | TN2019000187A1 (en) |
UA (1) | UA125311C2 (en) |
WO (1) | WO2018178060A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020176513A1 (en) * | 2019-02-25 | 2020-09-03 | Emory University | Chimeric compounds and methods of managing neurological disorders or conditions |
CN112430229A (en) * | 2020-11-24 | 2021-03-02 | 福建医科大学 | Compound for targeted degradation of PARP protein and preparation method and application thereof |
WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
EP4183781A4 (en) * | 2020-07-20 | 2024-01-03 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113292465B (en) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | Cysteine derivative and synthesis method and application thereof |
CN115957338A (en) * | 2021-10-12 | 2023-04-14 | 成都科岭源医药技术有限公司 | High-stability targeting joint-drug conjugate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015157595A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045307A (en) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | Antibody-drug conjugates and method |
CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
SG189817A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
US20170319709A1 (en) * | 2013-07-05 | 2017-11-09 | Formation Biologics Inc. | Egfr antibody conjugates |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/en active Search and Examination
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/en active Pending
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 UA UAA201909898A patent/UA125311C2/en unknown
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 EA EA201991985A patent/EA201991985A1/en unknown
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en unknown
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/en unknown
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/en active Pending
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/en not_active Application Discontinuation
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en active Pending
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015157595A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
Non-Patent Citations (58)
Title |
---|
AI T. ET AL., CURRENT MED CHEM, vol. 19, 2012, pages 475 |
AKHTAR, PLOS ONE, vol. 8, 2013, pages e67813 |
ALISON C. WEST ET AL: "The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects", ONCOIMMUNOLOGY, vol. 1, no. 3, 1 May 2012 (2012-05-01), pages 377 - 379, XP055406778, DOI: 10.4161/onci.18804 * |
BADIA, ANTIVIRAL RES, vol. 123, 2015, pages 62 - 9 |
BARON, J ONCOL PHARM PRACT, vol. 21, 2015, pages 132 - 42 |
BATTISTUZZI G ET AL., CURRENT BIOACTICE COMPOUNDS, vol. 12, 2016, pages 282 - 288 |
BERDASCO, HUM GENET, vol. 132, 2013, pages 359 - 83 |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, 2016, pages 1542 - 1545 |
BLANCO, vol. 20, 2014, pages 2311 - 6 |
BORNSTEIN, AAPS JOURNAL, vol. 17, 2015, pages 525 - 34 |
BURGESS AW, GROWTH FACTORS, vol. 26, 2008, pages 263 - 74 |
CASI; NERI, J MED CHEM, vol. 58, 2015, pages 8751 - 61 |
CHEM. SOC. REV., vol. 45, 2016, pages 1691 - 1719 |
CHOI S ET AL., J CONTROL. RELEASE, vol. 152, no. 1, 2011, pages e9 - e10a |
CHOI S ET AL: "Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 152, no. suppl. 1, 30 November 2011 (2011-11-30), pages e9 - e10, XP002720609, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2011.08.089 * |
CHONG CR, NAT MED, vol. 19, 2013, pages 1389 - 400 |
CHOUDHARY, SCIENCE, vol. 325, 2009, pages 834 - 40 |
CLAWSON, ANN TRANSL MED, vol. 4, 2016, pages 287 |
DINARELLO, CELL, vol. 140, 2010, pages 935 - 950 |
DINARELLO, MOL MED, vol. 17, 2010, pages 333 - 52 |
DUVIC, BLOOD, vol. 109, 2007, pages 31 - 39 |
ENRIQUE AA, FRONT BIOSCI, vol. 4, 2012, pages 12 - 22 |
FEINER, EXP REV PROTEOMICS, vol. 13, September 2016 (2016-09-01), pages 817 - 32 |
FELICE, ALIMENT PHARMACOL THER, vol. 41, 2015, pages 26 - 38 |
GARNOCK-JONES KP, DRUGS, vol. 75, 2015, pages 695 - 704 |
GIANFRANCO BATTISTUZZI ET AL: "Current Bioactive Compounds", 1 December 2016 (2016-12-01), XP055405704, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101637/pdf/CBC-12-282.pdf> [retrieved on 20170912], DOI: 10.2174/15734072126661605041605 * |
GIANNINI, FUTURE MED CHEM, vol. 4, 2012, pages 1439 - 60 |
GIANNINI, J MED CHEM, vol. 57, 2014, pages 8358 - 77 |
GLOZAK, ONCOGENE, vol. 26, 2007, pages 5420 - 32 |
GRAY, EPIGENOMICS, vol. 3, 2011, pages 431 - 450 |
GREEN, THEODORA W.; WUTS, PETER G.M.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS INC. |
GRYDER, FUTURE MED CHEM, vol. 4, 2012, pages 505 - 24 |
IZA DENIS ET AL: "Vorinostat-Polymer Conjugate Nanoparticles for Acid-Responsive Delivery and Passive Tumor Targeting", BIOMACROMOLECULES, vol. 15, no. 12, 7 November 2014 (2014-11-07), US, pages 4534 - 4543, XP055478748, ISSN: 1525-7797, DOI: 10.1021/bm501338r * |
LANDI L, EXPERT OPIN PHARMACOL THER, vol. 15, 2014, pages 2293 - 305 |
LEAL M, ANN NY ACAD SCI, vol. 1321, 2014, pages 41 - 54 |
LI T, TARGET ONCOL, vol. 4, 2009, pages 107 - 19 |
LOREDANA VESCI ET AL: "Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor", ONCOTARGET, vol. 6, no. 8, 20 March 2015 (2015-03-20), pages 5735 - 5748, XP055405708, DOI: 10.18632/oncotarget.3240 * |
MEI, NEURON, vol. 83, 2014, pages 27 - 49 |
MELLMAN, COLD SPRING HARB PERSPECT BIOL, vol. 5, 2013, pages a016949 |
MENDELSOHN J, SEMIN ONCOL, vol. 33, 2006, pages 369 - 85 |
MINUCCI, NATURE REV CANCER, vol. 6, 2006, pages 38 - 51 |
MOSESSON, NAT REV CANCER, vol. 8, 2008, pages 835 - 50 |
OKELEY, HEMATOL ONCOL CLIN NORTH AM, vol. 28, 2014, pages 13 - 25 |
OYAIS A ET AL., ZENTRALBL CHIR., vol. 141, 2014, pages 421 - 4 |
OYAIS A, ZENTRALBL CHIR., vol. 141, 2014, pages 421 - 4 |
PACHAIYAPPAN, BIOORG AND MED CHEM LETT, vol. 24, 2014, pages 21 - 32 |
RUOLAN GU, JOURNAL OF CHROMATOGRAPHY B, vol. 1000, 2015, pages 181 - 186 |
SAMANTA, BIOCHIM BIOPHYS ACTA, vol. 1863, 2017, pages 518 - 28 |
SOLASS ET AL., ANN SURG ONCOL, vol. 20, 2013, pages 3504 - 11 |
SOLASS W, ANN SURG ONCOL, vol. 21, 2014, pages 553 - 9 |
SOLASS, ANN SURG ONCOL, vol. 20, 2013, pages 3504 - 11 |
T. AI ET AL: "Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy", CURRENT MEDICINAL CHEMISTRY : THE NEW INTERNATIONAL JOURNAL FOR TIMELY IN-DEPTH REVIEWS IN MEDICINAL CHEMISTRY, vol. 19, no. 4, 1 February 2012 (2012-02-01), NL, pages 475 - 487, XP055406772, ISSN: 0929-8673, DOI: 10.2174/092986712798918842 * |
VANDERMOLEN, J ANTIBIOT (TOKYO, vol. 64, 2011, pages 525 - 531 |
VESCI, ONCOTARGET, vol. 20, 2015, pages 5735 - 48 |
WEST A.C. ET AL., ONCOIMMUNOLOGY, vol. 1, 2012, pages 376 |
WEST, J CLIN INVEST, vol. 124, 2014, pages 30 - 39 |
WILLIAM GUERRANT ET AL: "Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 4, 23 February 2012 (2012-02-23), pages 1465 - 1477, XP055478743, ISSN: 0022-2623, DOI: 10.1021/jm200799p * |
ZHANG, MED RES REV, vol. 35, 2015, pages 63 - 84 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020176513A1 (en) * | 2019-02-25 | 2020-09-03 | Emory University | Chimeric compounds and methods of managing neurological disorders or conditions |
EP4183781A4 (en) * | 2020-07-20 | 2024-01-03 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
CN112430229A (en) * | 2020-11-24 | 2021-03-02 | 福建医科大学 | Compound for targeted degradation of PARP protein and preparation method and application thereof |
CN112430229B (en) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | Compound for targeted degradation of PARP protein and preparation method and application thereof |
WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Also Published As
Publication number | Publication date |
---|---|
MX2019011492A (en) | 2019-11-01 |
JP2020515578A (en) | 2020-05-28 |
SG11201906543RA (en) | 2019-08-27 |
SG10202109654SA (en) | 2021-10-28 |
KR20190126824A (en) | 2019-11-12 |
EA201991985A1 (en) | 2020-02-25 |
CN110475572A (en) | 2019-11-19 |
BR112019013449A2 (en) | 2019-12-31 |
CA3047359A1 (en) | 2018-10-04 |
EP3381474A1 (en) | 2018-10-03 |
TN2019000187A1 (en) | 2020-10-05 |
EP3600444A1 (en) | 2020-02-05 |
UA125311C2 (en) | 2022-02-16 |
IL268821A (en) | 2019-10-31 |
US20210128740A1 (en) | 2021-05-06 |
AU2018241840A1 (en) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018178060A1 (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
TWI650312B (en) | Novel glycine amide compound | |
ES2815098T3 (en) | Linker Conjugates (ADCs) with KSP Inhibitors | |
JP6743015B2 (en) | Antibody drug conjugates (ADCs) with deglycosylated anti-TWEAKR antibody of KSP inhibitor | |
CN105636591B (en) | Ligand-cytotoxic drug conjugate, preparation method and application thereof | |
JP2018524321A (en) | Antibody drug complex (ADC) and antibody prodrug complex (APDC) having an enzyme cleavable group | |
JP2018524313A (en) | Antibody-drug complex of kinesin spindle protein (KSP) inhibitor with anti-B7H3 antibody | |
AU2012244675A1 (en) | Novel binder-drug conjugates (ADCs) and their use | |
TW201420118A (en) | Antibody-drug conjugate produced by binding through linker having hydrophilic structure | |
JP2023113639A (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
JP2018528161A (en) | Site-specific homogeneous complex with KSP inhibitor | |
JP2018524314A (en) | Antibody-drug complex of kinesin spindle protein (KSP) inhibitor with anti-B7H3 antibody | |
JP6782250B2 (en) | Bifunctional cytotoxic agent containing CTI pharmacophore | |
EP3720842A1 (en) | Acyl hydrazone linkers, methods and uses thereof | |
KR20210094568A (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | |
JP2022516427A (en) | Tubricin and Protein-Tubricin Conjugate | |
EA042689B1 (en) | ANTIBODY-DRUG CONJUGATES (KALS) BASED ON HDAC INHIBITORS AND APPLICATION IN THERAPY | |
KR20220108783A (en) | Compositions and Methods Related to Molecular Conjugation | |
KR20210065991A (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
EA043080B1 (en) | A CYTOTOXIC DRUG CONJUGATE AND A PRODRUG FORM OF THE SPECIFIED CONJUGATE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18712246 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3047359 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019013449 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20197028286 Country of ref document: KR Kind code of ref document: A Ref document number: 2019553113 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018241840 Country of ref document: AU Date of ref document: 20180327 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018712246 Country of ref document: EP Effective date: 20191028 |
|
ENP | Entry into the national phase |
Ref document number: 112019013449 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190627 |